Page 28 | Certara

On-Demand Webinar

Standards for All: Controlling Your Metadata for Vendors, Study Sites, and Submission Datasets

Director of Product, Certara's Pinnacle 21Senior Principal CDISC Consultant, Certara's Pinnacle 21Achieve submission ready conformance…

CertaraFebruary 7, 2025

On-Demand Webinar

Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling

With the release of Version 24, the Simcyp Simulator introduces cutting-edge enhancements that further elevate…

CertaraFebruary 7, 2025

Publication

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…

CertaraFebruary 6, 2025

Conference

ACDM

- - Booth

CertaraFebruary 5, 2025

Video

Behind the Science: Meet Pharmacometrics Expert Ahmed Abulfathi

CertaraFebruary 5, 2025

Fact Sheet

Strategic Regulatory Affairs

CertaraFebruary 4, 2025

Blog

Rolling NDA and BLA Submissions: Accelerate Your Review Timeline

We look at the growing regulatory trend of rolling NDA and BLA submissions to help…

CertaraFebruary 3, 2025

Press Coverage

2025 cell and gene challenges: Scalability, supply chain and manufacturing

Explore insights on 2025 challenges in cell and gene therapy, including commercial viability, with expert…

CertaraFebruary 3, 2025

On-Demand Webinar

Industrializing QSP: Using Generative AI to accelerate the Model Life Cycle

CertaraJanuary 31, 2025

Blog

Best Practices for International Pharma Content Roll-Out

January 31, 2025 Pharmaceutical market access, sales, and field teams rely on high-quality, effective content…

CertaraJanuary 31, 2025

Standards for All: Controlling Your Metadata for Vendors, Study Sites, and Submission Datasets

Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

ACDM

Behind the Science: Meet Pharmacometrics Expert Ahmed Abulfathi

Strategic Regulatory Affairs

Rolling NDA and BLA Submissions: Accelerate Your Review Timeline

2025 cell and gene challenges: Scalability, supply chain and manufacturing

Industrializing QSP: Using Generative AI to accelerate the Model Life Cycle

Best Practices for International Pharma Content Roll-Out

Newsletter sign up

Quick links

Solutions

Contact